Eventide Asset Management’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$11.6M Buy
9,812
+4,216
+75% +$4.97M 0.16% 142
2026
Q2
$6.81M Buy
5,596
+475
+9% +$485K 0.09% 166
2026
Q1
$4.62M Buy
5,121
+425
+9% +$431K 0.08% 166
2025
Q4
$5.06M Sell
4,696
-244
-5% -$233K 0.08% 168
2025
Q3
$3.68M Buy
4,940
+648
+15% +$482K 0.06% 149
2025
Q2
$3.34M Sell
4,292
-480
-10% -$373K 0.06% 149
2025
Q1
$3.94M Buy
4,772
+574
+14% +$478K 0.08% 148
2024
Q4
$3.24M Buy
4,198
+70
+2% +$58K 0.06% 159
2024
Q3
$3.66M Buy
4,128
+2,946
+249% +$2.65M 0.06% 145
2024
Q2
$1.07M Buy
1,182
+308
+35% +$246K 0.02% 160
2024
Q1
$680K Buy
+874
New +$622K 0.01% 157

Other funds holding LLY

Eventide Asset Management's LLY Position: Q3 2026 in Review

Eventide Asset Management increased its Eli Lilly (LLY) stake by 75% in Q3 2026, buying an estimated $4.97M and bringing the position to 9,812 shares worth $11.6M. The position accounts for 0.16% of the portfolio, ranked #142.

Eventide Asset Management first reported a position in LLY in Q1 2024 and has held it in 11 quarters since. 4,599 funds tracked by Wall St. Rank hold LLY as of Q3 2026.

  • Eventide Asset Management held 9,812 shares of Eli Lilly worth $11.6M as of Q3 2026.
  • Eventide Asset Management bought 4,216 Eli Lilly shares in Q3 2026, an estimated $4.97M.
  • Eli Lilly made up 0.16% of Eventide Asset Management's portfolio in Q3 2026, its #142 holding.
  • Eventide Asset Management first reported a position in Eli Lilly in Q1 2024 and has held it in 11 quarters since.
  • 4,599 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2026.

Based on Eventide Asset Management's 13F filing for Q3 2026, filed 13 Nov 2026.